Figure 2.

Elements addressing patient selection emerging from atezolizumab development.

Note: ^*Histology addresses differential combinations with atezolizumab in the frontline setting.

Abbreviations: IC, immune cells; PD-L1, programed death ligand-1; TC, tumor cells; Teff, T-effector gene signature; TMB, tumor mutation burden.